Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KEM2111
- Development stage
- Phase 1
- Lead developer
- Shenzhen Famayi Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Topical, Transdermal
01
Overview
KEM2111 is a topical gel patch formulation being developed by Shenzhen Famayi Pharmaceutical Technology for the treatment of melasma. The product utilizes a transdermal gel patch delivery system designed to provide sustained release of the active ingredient to the affected skin areas. Melasma is a common skin condition characterized by hyperpigmented patches, and KEM2111 aims to address this through a localized, controlled-release application. As of early 2025, the drug is in Phase 1 clinical development in China, where it is being evaluated for safety, tolerability, adhesion, and pharmacokinetics in healthy volunteers.
Beyond the preview
Go deeper on KEM2111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KEM2111.